Skip to main content
About
Corporate Supporters
Committee
Official Paperwork
Position Papers and Guidelines
Reach and Representation
ABCD chairmen and their reports and bulletins
Contact Us
Become a Member
Join
Events
ABCD Events
Other Events
Travel Grant Scheme
Event Terms and Conditions
Submit an Abstract
Event Archive
Research & Audit
Endobarrier Studies
ABCD Nationwide Audits
ABCD audits on N3
Worldwide Endobarrier Registry
ABCD Nationwide FreeStyle Libre Audit
Journal
Current Issue
Instructions for Authors
Submit a manuscript
Editorial Team
Other Journals
Subscribe
Lifelong Learning
Resources
Consultant Development Programme
National Diabetes Consultant Mentorship Programme
Consultant Strategic Leadership Programme
Joint British Diabetes Societies for Inpatient Care
Diabetes & Endocrine Trainees
DTN-UK
Join
Committee
Events
Resources
Corporate Supporters
Newsletters
Best Practice Guides
Flash Glucose Monitoring Education
Webcast 1
Webcast 2
Webcast 3
Type 1 Collaborative
Join
Webinars
Newsletters
Login
You are here:
Home
Position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)
Position statement on use of SGLT-2 inhibitors in tpe 1 diabetes
Discipline:
Diabetes
Clinical taxonomy:
Treatments for diabetes
Resource taxonomy:
Position Paper
Follow Us